These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 16800083)

  • 1. [The mechanism of liver fibrosis become clearer. Drugs against the fibrotic process coming].
    Hultcrantz R
    Lakartidningen; 2006 May 17-30; 103(20):1588-9. PubMed ID: 16800083
    [No Abstract]   [Full Text] [Related]  

  • 2. Liver fibrosis and chronic viral hepatitis.
    Gutierrez-Reyes G; Gutierrez-Ruiz MC; Kershenobich D
    Arch Med Res; 2007 Aug; 38(6):644-51. PubMed ID: 17613356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Lhx2 seems to inhibit the development of liver cirrhosis. Gene discovery makes the development of drugs against this enormous health problem possible].
    Carlsson L; Danielsson A
    Lakartidningen; 2006 May 17-30; 103(20):1594-7. PubMed ID: 16800084
    [No Abstract]   [Full Text] [Related]  

  • 4. [Clinical application of non-invasive diagnosis for hepatic fibrosis].
    Cho SW; Cheong JY
    Korean J Hepatol; 2007 Jun; 13(2):129-37. PubMed ID: 17585186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of genetic polymorphisms in the progression of liver fibrosis in chronic hepatitis C virus infection.
    Papatheodoridis GV; Paraskevis D
    Liver Int; 2008 Jul; 28(6):764-6. PubMed ID: 18647140
    [No Abstract]   [Full Text] [Related]  

  • 6. Precision-cut fibrotic rat liver slices as a new model to test the effects of anti-fibrotic drugs in vitro.
    van de Bovenkamp M; Groothuis GM; Meijer DK; Olinga P
    J Hepatol; 2006 Nov; 45(5):696-703. PubMed ID: 16828918
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies.
    Popov Y; Patsenker E; Stickel F; Zaks J; Bhaskar KR; Niedobitek G; Kolb A; Friess H; Schuppan D
    J Hepatol; 2008 Mar; 48(3):453-64. PubMed ID: 18221819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Noninvasive monitoring of hepatitis C fibrosis progression.
    Kotlyar DS; Blonski W; Rustgi VK
    Clin Liver Dis; 2008 Aug; 12(3):557-71, viii. PubMed ID: 18625428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver fibrosis: searching for cell model answers.
    Gutiérrez-Ruiz MC; Gómez-Quiroz LE
    Liver Int; 2007 May; 27(4):434-9. PubMed ID: 17403182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effect of pegylated interferon beta-1a therapy on the liver fibrosis in chronic hepatitis C: a semi-quantitative analysis].
    Rao HY; Li J; Zhang LF; Chen HY; Zhu LM; Wei L; Sun Y; Wang H
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):96-100. PubMed ID: 18353212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrosis and cirrhosis reversibility - molecular mechanisms.
    Gieling RG; Burt AD; Mann DA
    Clin Liver Dis; 2008 Nov; 12(4):915-37, xi. PubMed ID: 18984474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease.
    Ekstedt M; Franzén LE; Holmqvist M; Bendtsen P; Mathiesen UL; Bodemar G; Kechagias S
    Scand J Gastroenterol; 2009; 44(3):366-74. PubMed ID: 19016382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of D-penicillamine on liver fibrosis and inflammation in Wilson disease.
    Kazemi K; Geramizadeh B; Nikeghbalian S; Salahi H; Bahador A; Reza Nejatollahi SM; Dehghani SM; Dehghani M; Kakaei F; Malek-Hosseini SA
    Exp Clin Transplant; 2008 Dec; 6(4):261-3. PubMed ID: 19338486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elucidation of the role of COX-2 in liver fibrogenesis using transgenic mice.
    Yu J; Wu CW; Chu ES; Hui AY; Cheng AS; Go MY; Ching AK; Chui YL; Chan HL; Sung JJ
    Biochem Biophys Res Commun; 2008 Aug; 372(4):571-7. PubMed ID: 18503750
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing liver fibrosis.
    Castera L
    Expert Rev Gastroenterol Hepatol; 2008 Aug; 2(4):541-52. PubMed ID: 19072402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of liver biopsy in the assessment of hepatic fibrosis--its utility and limitations].
    Jin SY
    Korean J Hepatol; 2007 Jun; 13(2):138-45. PubMed ID: 17585187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversibility of hepatic fibrosis and cirrhosis--is it all hype?
    Friedman SL
    Nat Clin Pract Gastroenterol Hepatol; 2007 May; 4(5):236-7. PubMed ID: 17476207
    [No Abstract]   [Full Text] [Related]  

  • 18. Application of metabonomics on an experimental model of fibrosis and cirrhosis induced by thioacetamide in rats.
    Constantinou MA; Theocharis SE; Mikros E
    Toxicol Appl Pharmacol; 2007 Jan; 218(1):11-9. PubMed ID: 17113614
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic stellate cells and the reversal of fibrosis.
    Kisseleva T; Brenner DA
    J Gastroenterol Hepatol; 2006 Oct; 21 Suppl 3():S84-7. PubMed ID: 16958681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation.
    Luk JM; Wang X; Liu P; Wong KF; Chan KL; Tong Y; Hui CK; Lau GK; Fan ST
    Liver Int; 2007 Sep; 27(7):879-90. PubMed ID: 17696925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.